Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2026-05-07 AGM Information
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BioSenic SA_Information on shareholders' rights AGM_FR_Final(1577995.2).pdf
AGM Information Classification · 95% confidence The document is a detailed notice concerning shareholder rights related to the upcoming Annual General Meeting (AGM) of BioSenic scheduled for June 10, 2026. It outlines shareholders' rights to add agenda items, submit proposals, and ask questions in writing before the AGM. The content focuses on procedural information about the AGM rather than financial results, management changes, or other report types. There is no financial data or report attached, nor is it an announcement of voting results or proxy solicitation. The document fits the description of materials shared during the AGM, specifically information about shareholder rights and meeting procedures, which aligns with the AGM Information category.
2026-05-07 French
BioSenic SA_proxy AGM_FR_Final(1577975.2).pdf
AGM Information Classification · 100% confidence The document is a proxy form (procuration) for shareholders to be represented at the Annual General Meeting (AGM) scheduled for June 10, 2026. It includes detailed instructions for voting on agenda items related to the approval of annual statutory and consolidated accounts, the board's annual report, the auditor's report, remuneration report, discharge of directors and auditors, and renewal of board mandates. The document is clearly related to the AGM process and contains the agenda and voting proposals for the AGM. It is not the actual annual report or financial statements but a proxy form for the AGM where these reports will be discussed and approved. Therefore, the document fits the category of AGM Information (AGM-R). The document length is sufficient and contains detailed AGM-related content, not just an announcement or a brief notice, so it is not an RPA or RNS.
2026-05-07 French
BIOS_PR AGM 2026_FR_final(1574246.1).pdf
AGM Information Classification · 95% confidence The document is a press release dated May 7, 2026, announcing the date and details of BioSenic's upcoming Annual General Meeting (AGM) scheduled for June 10, 2026. It mentions the availability of preparatory documents for the AGM on the company's website and how shareholders can request these documents. The text does not contain any financial statements, detailed financial performance data, or management discussion. It is primarily an announcement about the AGM and the availability of related documents, not the AGM materials themselves or the meeting results. The document length is 4721 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, according to the classification rules, this document fits best under AGM Information (AGM-R), as it relates to the AGM and the preparatory materials for it.
2026-05-07 French
BioSenic SA_Convening notice AGM_FR_Final(1574100.2).pdf
AGM Information Classification · 100% confidence The document is a convocation notice for the Annual General Meeting (AGM) of BioSonic scheduled for June 10, 2026. It includes the agenda items such as the presentation and approval of statutory and consolidated annual accounts for the fiscal year ending December 31, 2025, the annual report of the board, the auditor's report, remuneration report, discharge of directors and auditors, and renewal of board mandates. It also details procedural information about participation, voting rights, proxies, and availability of documents. The document does not contain the actual annual report or financial statements but rather serves as the official meeting notice and agenda for the AGM. Therefore, it fits the category of AGM Information (AGM-R).
2026-05-07 French
BioSenic Rapport annuel 2025.pdf
Annual Report Classification · 100% confidence The document is titled 'Rapport Annuel 2025' which translates to 'Annual Report 2025'. It contains detailed sections typical of an annual report such as general information, management report, organizational structure, governance, related party transactions, shareholders, statutory accounts, and auditor's report. It references compliance with Belgian corporate law and financial regulations, includes a letter to shareholders, company strategy, and financial restructuring details. The document length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. Therefore, this document is the official yearly report covering company activity and full financial performance, fitting the definition of an Annual Report (10-K).
2026-04-30 French
BioSenic Rapport annuel 2025FR.xhtml
Annual Report Classification · 100% confidence The document is titled 'BioSenic Rapport annuel 2025' which translates to 'BioSenic Annual Report 2025'. It contains a detailed table of contents including general information, management report, organizational structure, corporate governance, related party transactions, shareholders, statutory accounts, and auditor's report. The text references compliance with Belgian corporate law and financial reporting requirements, mentions audited annual financial statements, and includes a letter to shareholders discussing the company's strategy and financial restructuring. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. These characteristics clearly identify the document as a full Annual Report covering the company's activities and financial performance for the fiscal year ending December 31, 2025. FY 2025
2026-04-30 French

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.